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Background: Diabetes and cerebral ischemic-reperfusion are among the most common causes of neurological
complications in Egypt. The prevalence of diabetes in Egypt is high and it can be considered as a major clinical and
public health problem.
Methods: Blood glucose, lipid profile, oxidative stress makers (cerebral MDA & GSH), cerebral interleukin-4 (IL-4)
level and cerebral cyclooxygenase-2 (COX-2) gene expression were measured in male albino rats weighing 200 ±
20 g. The rats were divided into five groups, normal control group, diabetic group (diabetes was induced by single
dose of streptozotocin [STZ]), diabetic cerebral ischemic-reperfused group, two treated groups (diabetic and diabetic
ischemic-reperfused), both groups treated with resveratrol. Histological study was done using H&E, AgNOR and cresyl
violet stains. Immunohistochemistry for Bax and COX-2 was done with morphometric study.
Results: Diabetic and diabetic cerebral ischemic- reperfused rats showed significant increase in serum glucose level,
serum TAG, serum LDL-C, atherogenic index, cerebral MDA and upregulation of COX-2 gene expression. These groups
showed significant decrease in serum HDL, cerebral IL-4 and depletion of cerebral GSH when compared to normal
control rats. Treating these groups with resveratrol resulted in significant decrease in serum glucose level, serum TAG,
TC, serum LDL-C, atherogenic index, cerebral MDA and downregulation of COX-2 gene expression. The results of
COX-2 gene expression were confirmed by COX-2 immunohistochemistry. Also, significant increase in serum HDL,
cerebral IL-4 and cerebral GSH contents could be observed in these treated groups as compared to normal control
group. Cerebral apoptotic index and optical density of Bax reaction revealed significant increase in diabetic and diabetic
cerebral ischemic-reperfused rats while treatment of these groups with resveratrol resulted in significant decrease in
cerebral apoptotic index and optical density of Bax reaction. These apoptotic results were confirmed with AgNOR and
cresyl violet stains.
Conclusion: The results of this research suggest that upregulation of cerebral COX-2 gene along with the decrease in
cerebral IL-4 and enhanced cerebral apoptosis is critically involved in cerebral damage associated with diabetes and
cerebral ischemic-reperfusion. Resveratrol can ameliorate these effects and has promising neuroprotective effect in
diabetic-induced cerebral complications.
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Diabetes mellitus is a chronic metabolic disorder, char-
acterized by disturbed glucose metabolism due to an ab-
solute or relative insulin deficiency [1]. The prevalence
of diabetes in Egypt is high and it can be considered as a
major clinical and public health problem [2]. Neuro-
logical complications are among the central problems in
diabetes mellitus. Over 60% of individuals with diabetes
are affected by neurological disorders [3]. Diabetic neur-
opathy is attributed to chronic hyperglycemia which
may induce damage to nerve cells and decrease neuro-
vascular flow especially during neuronal ischemia [4].
Cerebral ischemia is a leading cause of death and disabil-
ity worldwide and diabetes is a risk factor for ischemic
cerebrovascular diseases [5]. Reperfusion following cere-
bral ischemia leads to the generation of pro-oxidant spe-
cies which cause neuronal damage by acting directly on
macromolecules, including proteins, lipids and DNA, or
indirectly by interfering with cell signaling pathways and
gene expression regulation [6]. Furthermore, several mech-
anisms are responsible for diabetic neuropathy including
dyslipidemia, inflammation and apoptosis [4,7,8].
The most proposed molecular mechanism by which
hyperglycemia induces complications in diabetes is in-
creased oxidative stress [9]. Oxidative stress is a relative
overload of oxidants caused by increased free radical
production and/or decreased antioxidant defense sys-
tems. Increased free radical production exerts toxic effects
on membrane phospholipids, resulting in formation of
toxic products such as MDA [1,10].
Diabetes is usually associated with inflammation [8].
When excess glucose is shunted through alternative
metabolic pathways, this leads to increase in TGF-β1
and NF-κB (inflammatory mediators). COX-2 is an im-
portant enzyme that is upregulated by NF-κB, which is
observed in peripheral nerves and vascular tissues in ex-
perimental diabetes. Pharmacological blockade or gene
ablation of COX-2 prevents diabetes-induced changes in
peripheral nerves [4]. Also, COX-2 enzyme is respon-
sible for the production of prostaglandins, a family of
powerful inflammatory mediators produced by activated
microglia in the neuroinflammatory/neurodegenerative
diseases, and not surprisingly, COX-2 has been consid-
ered a major therapeutic target [11]. IL-4 has been dem-
onstrated to have anti-inflammatory activities specially on
activated microglia, including inhibition of the expression
of TNF-α, as well other pro-inflammatory cytokines [12].
Apoptosis, programmed cell death, can contribute to a
variety of disease states in the nervous system such as dia-
betes, ischemia and Alzheimer’s disease [13].
Resveratrol, naturally occurring polyphenol, is found
in high concentration in the skin and seeds of grapes,
peanuts and ground nuts and has been reported to have
several biological effects, including a potent antioxidativeeffect via preventing lipid peroxidation, cardioprotective,
anticancer, and anti-inflammatory activity attributed to
COX-2 inhibition [10,14]. Moreover, resveratrol may be
helpful in preventing and treating some metabolic dis-
eases, including diabetes through reduction of blood glu-
cose, preservation of cells, and improvement in insulin
action [14]. In addition, resveratrol can reduce the oxi-
dative stress produced in STZ-diabetic rats. [15]. It has
been reported that resveratrol administration to the
hypercholesterimic rats attenuated the increase in serum
lipid profile [16].
The present study was designed to clarify the adverse
effects of diabetes on cerebral outcomes, evaluate the ef-
fect of resveratrol on modulating cerebral complications
in diabetic and diabetic cerebral ischemic-reperfused rats
and investigate the histological changes in cerebral tissue




Adult male albino rats (200 ± 20 g), purchased from The
Egyptian Organization for Biological Products and Vac-
cines (Cairo, Egypt), were housed in stainless steel cages
at room temperature (25 ± 2°C) and humidity of 65-69%
and maintained on 12 hours light/dark cycle. Rats were
fed on rodent chow (El-Nassr Pharmaceuticals. Co.,
Egypt). This protocol was approved by the Animal Care
and Use Committee of Biochemistry Department, Faculty
of Pharmacy, Zagazig University, Egypt.
Experimental design
Induction of diabetes
One week after acclimatization, rats were fasted over-
night. Diabetes was induced by intraperitoneal injection
of a single dose of freshly prepared solution of streptozo-
tocin (STZ) (45 mg/kg body weight) (Sigma Chemical
Co. St. Louis, USA.) dissolved in 0.5 ml of 0.01 M cold
sodium citrate buffer, pH = 4.5. One week later, blood
samples were collected and processed for blood glucose
determination. Rats which achieved fasting serum glu-
cose level ≥200 mg/dl were considered diabetic and se-
lected for this study [17].
About 20% morbidity rate was shown during induction
of diabetes and about 10% of animals were resistant and
did not achieve the required serum glucose level. Rats
were divided into two groups of 20 animals each. The
first group: diabetic rats received equal amount of ve-
hicle (distilled water with 3-5% w/v gum acacia), this
group served as diabetic control (D) group. The second
group: diabetic rats treated with resveratrol. Resveratrol
(MegaResveratrol®) was supplied from Mega Resveratrol
and Candlewood Stars Inc., USA, and given orally in a
dose level 20 mg/kg body weight [18,19] through the
Table 1 Sequence of primers used in the experiment
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tion of cerebral ischemic-reperfusion. Due to the limited
water solubility of this drug, 3-5% w/v gum acacia was
used as a suspending agent.
Another group of normal rats received equal amount
of vehicle (distilled water with 3-5% w/v gum acacia)
represents the normal control (N) group.
At the end of the treatment period, the rats were
fasted overnight and the previously mentioned groups
were divided into two subgroups. The first set of animals
was anesthetized using intraperitoneal injection of ureth-
ane (1.25 g/kg) and subjected to blood sampling, decapi-
tation and cerebral tissue sampling. The second set of
animals was subjected to induction of cerebral ischemic-
reperfusion.
Induction of cerebral ischemic-reperfusion
After anesthesia, each rat was fixed on thermostatically
controlled heating pad. A rectal thermometer was inserted
and body temperature kept at 37°C and both common ca-
rotid arteries were exposed by a midline incision. Each ca-
rotid artery was freed from its adventitial sheath and
vagus nerve, which was carefully separated and main-
tained. Ischemia was achieved by clamping the bilateral
common carotid arteries for 30 min. Recirculation of
blood flow was established by declamping and restoration
of blood flow in the carotid arteries was confirmed by
careful observation. Reperfusion was allowed for 60 min.
[20]. All rats of (N), (D) and (D + Res) groups were sub-
jected to the previous procedure except for clamping of
carotid arteries and reperfusion.
At the end of this time, the rats were subjected to
blood sampling, decapitation and cerebral tissue sam-
pling. Blood was collected via Retro-orbital bleeding in a
dry centrifuge tube, and centrifuged at 3000 rpm for
15 minutes for serum separation. Fresh serum samples
were processed immediately for determination of glu-
cose level. The remainder serum samples were stored as
aliquots at −20°C for subsequent determination of triac-
ylglycerol (TAG), total cholesterol (TC) and high density
lipoprotein cholesterol (HDL-C).
Following blood collection, rats were killed by decapi-
tation. The brain from each animal was removed, then
either washed with 0.9% NaCl. and quickly frozen in li-
quid nitrogen (−169°C) for 5 minutes then stored at
−20°C for further determination of lipid peroxidation in
the form of MDA, GSH content, IL-4 level, as well as
gene expressions of COX-2 or kept in 10% formalin
solution.
Biochemical assays in the serum
The following Parameters were measured in the serum
using commercial kits provided by Spinreact, Co., Spain.:
Glucose [21], triacylglycerol [22], cholesterol [23] andHDL-C [24]. Serum LDL-C was determined using the
formula of Friedewald et al. [25]. Furthermore, athero-
genic index was calculated according to the formula of
Sharma et al. (atherogenic index = LDL-C/HDL-C) [26].
Biochemical assays in cerebral tissues
Cerebral MDA was determined spectrophotometrically as
a marker of lipid peroxidation by using thiobarbituric acid
reagent, according to modified method of Buege and Aust
[27]. GSH content was measured spectrophotometrically
using Ellman’s reagent, according to the modified method
of Ahmed et al. [28]. Also, cerebral IL-4 was determined
according to Nolan et al. [29] by solid phase Enzyme
Linked Immuno Sorbent Assay (ELISA) using rat IL-4 kit
(RayBiotech, USA) and a microtiter plate reader capable
of reading at 450 nm.
Molecular biology assays in the cerebral tissues
RNA extraction
Total RNA was extracted from cerebral tissues using SV
Total RNA isolation system (Promega, Madison, WI,
USA) according to the manufacturer’s instructions.
Gene expression of COX-2
For amplification of target COX-2 gene, RT-PCR was run
as 2 separate steps. Briefly, equal amounts of total RNA
were reverse transcribed using the Moloney murine
leukemia virus reverse transcriptase (Promega, Madison,
Wisconsin), ribonuclease inhibitor (Promega), deoxynu-
cleoside 5′ triphosphate and oligo-dT primer. The reac-
tion was terminated by heating to 95 C for 10 minutes,
followed by cooling to 4 C. The complementary DNA
samples were amplified in the presence of Taq DNA poly-
merase (Promega), deoxynucleoside 5′ triphosphate, and
the appropriate primer pairs (primers, annealing tempera-
tures, number of PCR cycles and product sizes are listed
in Table 1).
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The PCR products were electrophoresed on 2% agarose
gel, stained with ethidium bromide and visualized by
UV transilluminator. It was performed using the gel
documentation system (BioDO, Analyzer) supplied by
Biometra (Gottingen, Germany).
Histological studies
Cerebral tissues were kept in 10% formalin for at least
1 week, then dehydrated using ascending grades of ethyl
alcohol (70%, 90% and 100%), then cleaned in xylene
and embedded in paraffin. Cross sections of about 4 μm
thickness were cut with a microtome, mounted on glass
slides and stained with:
– Routine Hematoxylin and eosin (H&E) stain [30].
The sections were then examined under light
microscope for histological changes.
– AgNOR stain [31]. AgNOR stained sections were
examined under the light microscope then AgNOR
dots were counted as brown dots in the nuclei of
cells using 40× objective lens. 50 cells were studied
in each case and the mean AgNOR per nucleus was
calculated.
– Cresyl violet stain [32]. Neuronal quantification was
done under 40× lens of light microscope. Ten high
power fields from each group were randomly
selected for cell quantification. The number of viable
cells had lightly stained nuclei while dark stained




The cerebral cortex sections were processed according to
[33] using polyclonal COX-2 antibody (Thermo ScientificTable 2 Effect of resveratrol on serum glucose, oxidative stre
N D
Serum glucose (mg/dl) 103.3 ± 8.2 341.8 ± 21.42
Cerebral MDA (nmol/g.tissue) 178.8 ± 14.18 442.0 ± 17.05
Cerebral GSH (nmol/g.tissue) 320.5 ± 26.73 141.2 ± 17.79
Serum TAG (mg/dl) 72.5 ± 6.95 204.8 ± 14.66
Serum TC (mg/dl) 77.83 ± 6.62 164.7 ± 14.58
Serum HDL-C (mg/dl) 26.67 ± 2.07 17 ± 1.52*
Serum LDL-C (mg/dl) 36.67 ± 4.68 106.7 ± 12.29
Atherogenic index 1.37 ± 0.21 6.33 ± 1.11*
All results were expressed as mean ± SD, (n = 6).
*Significantly different from N at P < 0.01.
#Significantly different from D at P < 0.01.
aSignificantly different from D at P < 0.05.
bSignificantly different from DIR at P < 0.05.
N, D, D + Res, DIR, DIR + Res represent control, diabetic, diabetic treated with resver
ischemic-reperfusion treated with resveratrol groups.Pierce™ Catalog #: PA1-37505 , dilution 1:100). Then mor-
phometric study was done to measure the optical density
of COX-2 reaction in ten high power fields using a (Leica
Qwin 500, England) image analyzer.
Bax (an apoptotic marker) Immunohistochemical reaction
The cerebral cortex sections were processed according
to [34] using monoclonal Bax antibody (Thermo Fisher
Scientific™ Catalog #: MA5-14003 , dilution 1:50). Then
morphometric study was done to count the apoptotic
cells to calculate cerebral apoptotic index (ratio of apop-
totic cells to normal cells) and measure the optical dens-
ity of Bax reaction. This study was carried out using a
(Leica Qwin 500, England) image analyzer in 10 high
power fields.
Statistical analysis
All results were expressed as Mean ± SD. Statistical ana-
lysis was performed using SPSS program (version 16;
SPSS Inc., Chicago, Illinois, USA). Student “t” test and
the analysis of variance (one way ANOVA) were used
for comparison between groups [35].
Results
Biochemical and hematologic parameters
Table 2 illustrates that administration of a single dose of
STZ to normal adult male albino rats induced diabetes
as indexed by a significant increase (three folds) in serum
glucose level, dyslipidemia as shown by a significant eleva-
tion of serum TAG, TC, serum LDL-C and atherogenic
index and a significant decrease in serum HDL-C and fi-
nally a significant increase in cerebral MDA and depletion
of cerebral GSH content as compared to normal rats.
Also, cerebral ischemic-reperfusion in diabetic rats re-
sulted in a significant increase in cerebral MDA contentss markers and lipid profile in studied groups
D + Res DIR DIR + Res
* 241.3 ± 10.63a 348.5 ± 10.8* 261.7 ± 14.83b
* 271.8 ± 29.4a 974.8 ± 45.19*# 684.8 ± 51.16b
* 234.7 ± 12.42a 100.7 ± 13.8*# 226.3 ± 9.81b
* 121.3 ± 10.75a 220.5 ± 12.34* 127 ± 11.25b
* 107.8 ± 10.17a 168.3 ± 14.42* 111.9 ± 10.54b
22.17 ± 1.6a 16.02 ± 1.44* 20.87 ± 1.48b
* 61.4 ± 9.78a 108.2 ± 12.81* 65.62 ± 10.06b
2.77 ± 0.55a 6.83 ± 1.25* 3.18 ± 0.57b
atrol, diabetic with cerebral ischemic-reperfusion, diabetic with cerebral
DNA
Ladder
N D D+Res  DIR DIR+Res
COX-2
-actin
Mohamed et al. Diabetology & Metabolic Syndrome 2014, 6:88 Page 5 of 14
http://www.dmsjournal.com/content/6/1/88and a significant depletion of cerebral GSH in comparison
to the diabetic group (D).
Treatment of the diabetic group and the diabetic
group with cerebral ischemic-reperfusion with resvera-
trol for six weeks resulted in a significant decrease in
serum glucose level, serum TAG, TC, serum LDL-C,
atherogenic index and cerebral MDA and a significant
increase in serum HDL-C and cerebral GSH content
when compared to the corresponding control groups.
Effect of resveratrol on cerebral IL-4
Diabetic rats and diabetic rats with cerebral ischemic-
reperfusion showed significant decrease in cerebral IL-4
when compared to the normal control group. While
treatment of these rats with resveratrol for six weeks re-
sulted in a significant elevation of cerebral IL-4 in com-
parison to the corresponding control groups Figure 1.
Effect of resveratrol on cerebral COX-2 gene expression
The diabetic group and the diabetic group with cerebral
ischemic-reperfusion showed a significant upregulation
of cerebral COX-2 gene expression while treatment of
these groups with resveratrol for six weeks led to signifi-
cant downregulation of cerebral COX-2 gene expression
in comparison to the corresponding control groups
Figure 2.
Histological results
In H&E-stained sections, the cerebral cortex of the nor-
mal control group was covered by pia matter containing
blood vessels. Six layers were identified in the cerebral
cortex; outer molecular layer, external granular layer, ex-
ternal pyramidal layer, inner granular layer, inner pyram-
idal, and the polymorphic layer. The molecular layer was
thick and contained dense plexus of nerve fibers with
few cells. Whereas, the external granular and external*
*#
Figure 1 Effect of resveratrol on cerebral IL-4 content in studied
groups. (*) Significantly different from N at P < 0.01. (#) Significantly
different from D at P < 0.01. (a) Significantly different from D at
P < 0.05. (b) Significantly different from DIR at P < 0.05.pyramidal contained numerous granular cells and pyr-
amidal cells. While the internal granular and internal
pyramidal showed few granular cells and pyramidal cells.
The pyramidal cell had multipolar shape with basophilic
cytoplasm and large, rounded vesicular nucleus. Granu-
lar cells could be seen with large open face nuclei, prom-
inent nucleolus and little cytoplasm. The pink-stained
background was the neuropil Figure 3-A, B, C.
Light microscope examination of H&E stained sections
of cerebral cortex of the diabetic and diabetic cerebral
ischemic-reperfused groups showed a picture of eosino-
philic degeneration of pyramidal cells. The cells ap-
peared contracted, lost their processes with eosinophilic
cytoplasm and small, darkly stained nuclei. Some neu-
rons; surrounded by halos could be observed Figure 3-D,
E, F. On the other hand, treatment of diabetic rats and
diabetic cerebral ischemic-reperfused rats with resvera-
trol resulted in moderate improvement of cerebral tis-
sue. Resveratrol restored the normal architecture of
cerebral tissue to some extent. Some of cells appeared
normal in shape however, other cells showed a picture of
eosinophilic degeneration, Figure 3-G, H.
Examination of cerebral cortex sections stained with
AgNOR stain revealed that AgNOR positive stainFigure 2 Effect of resveratrol on relative cerebral COX-2 gene
expression (COX-2/β-actin) in studied groups. An agarose gel
electrophoresis showed PCR products of mRNA gene expression
level of COX-2 gene and normal control gene (β-actin). Lane
DNA ladder: 100pb DNA marker, lanes N, D, D + Res, DIR, DIR + Res
represent control, diabetic, diabetic treated with resveratrol,
diabetic with cerebral ischemic-reperfusion, diabetic with cerebral
ischemic-reperfusion treated with resveratrol groups. (*) Significantly
different from N at P < 0.01. (#) Significantly different from D at
P < 0.01. (a) Significantly different from D at P < 0.05. (b) Significantly
different from DIR at P < 0.05.
Figure 3 (See legend on next page.)
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Figure 3 Photomicrographs of sections in the cerebral cortex of adult male albino rats. (A) control group showing pia matter containing
blood vessel (arrow). Six layers are identified in the cerebral cortex; outer molecular layer (I), external granular layer (II), external pyramidal layer
(III), inner granular layer (IV), inner pyramidal (V), and the polymorphic layer (VI). Also, white matter can be seen. (B) higher magnification of the
previous section. (C) control group showing normal pyramidal cell (P). This cell has multipolar shape with basophilic cytoplasm and large,
rounded vesicular nucleus (arrow). Granular cells (G) can be seen with large open face nuclei, prominent nucleolus and little cytoplasm. The pink-
stained background is the neuropil (N) (D) diabetic group showing pia matter (arrow), dilated blood vessel (short arrow). (E) diabetic group showing
eosinophilic degeneration in pyramidal cells, noticed by contracted cells with loss of cell processes, eosinophilic cytoplasm and small darkly
stained nucleus (arrow). Some cells are surrounded with halos (F) diabetic cerebral ischemic-reperfused group showing eosinophilic degeneration in
all pyramidal cells, noticed by shrunken cells with loss of their processes, eosinophilic cytoplasm and small darkly stained nucleus (arrow). Some cells
are surrounded with halos. Many congested blood vessels can be noticed (short arrows). (G) diabetic group treated with resveratrol showing many
pyramidal cells with normal shape (P). However, some cells still show features of eosinophilic degeneration (arrow). (H) diabetic cerebral ischemic-
reperfused group treated with resveratrol showing the similar results as in diabetic group treated with resveratrol. [A→H&Ex40 (scale bar represents
100 μm), B, D→H&Ex100 (scale bars represent 40 μm), C, E, F, G, H→H&E stain x400 (scale bars represent 10 μm)].
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The mean AgNOR counts were significantly low in the
diabetic and diabetic ischemic-reperfused groups when
compared to the normal control group. In the diabetic
and diabetic ischemic-reperfused groups treated with
resveratrol, mean AgNOR counts showed a moderate in-
crease (but not significant) when compared to the dia-
betic and diabetic ischemic-reperfused groups Figure 4
and Table 3.
Microscopic examination of cerebral cortex sections
stained with cresyl violet stain of the studied groups
showed pathological changes. Upon quantification of vi-
able cells in cerebral cortex, the diabetic and diabetic
ischemic-reperfused groups exhibited decrease (not sig-
nificant in the diabetic group and significant in the dia-
betic ischemic-reperfused group) in the mean number of
surviving neurons when compared to the normal control
group. While the treated groups with resveratrol re-
vealed a moderate increase (not significant in the dia-
betic treated group and significant in the diabetic
ischemic-reperfused treated group) in the mean number
of surviving neurons Figure 5 and Table 3.
COX-2 immunoexpression appeared as brown cytoplas-
mic reaction. Immunohistochemical examination of cere-
bral cortex sections of the normal control group showed
weak positive immunoreactions for COX-2 Figure 6-A.
The diabetic and diabetic ischemic-reperfused groups
showed strong positive immunoreaction for COX-2,
Figure 6-B, C. On the other hand, the diabetic and dia-
betic ischemic-reperfused groups treated with resvera-
trol revealed moderate immunoreaction for COX-2,
Figure 6-D, E.
Table 3 showed significant increase in the mean of the
optical density of COX-2 immunoreaction in the dia-
betic and diabetic cerebral ischemic-reperfused groups
in comparison to the normal control group. On the
other, treatment of the diabetic and diabetic cerebral
ischemic-reperfused groups with resveratrol resulted in a
significant reduction in the mean of optical density ofCOX-2 immunoreaction in comparison to the corre-
sponding control groups.
Immunohistochemical examination of cerebral cortex
sections of the normal control group showed weak
positive immunoexpression for Bax, Figure 7-A. How-
ever, cerebral cortex of the diabetic and diabetic
ischemic-reperfused groups showed strong positive im-
munoreaction for Bax, Figure 7-B, C. Conversely, im-
munohistochemical examination of the cerebral cortex
of the diabetic and diabetic ischemic-reperfused groups
treated with resveratrol revealed moderate immunore-
action for Bax, Figure 7-D, E.
Table 4 showed significant cerebral apoptosis mea-
sured by a significant increase in cerberal apoptotic
index (ratio of apoptotic cells to normal cells) and the
mean optical density of Bax immunoreaction in the dia-
betic and diabetic cerebral ischemic-reperfused groups
in comparison to the normal control group. On the
other hand, treatment of the diabetic and diabetic cere-
bral ischemic-reperfused groups with resveratrol resulted
in a significant reduction of cerberal apoptotic index and
the mean optical density of Bax immunoreaction in
comparison to the corresponding control groups.
Discussion
Administration of STZ (45 mg/kg) in adult male albino
rats resulted in induction of diabetes that was confirmed
by a remarkable increase in serum glucose level as com-
pared to normal rats. Other symptoms such as weight
loss, polyuria, polydepsia and polyphagia were also ob-
served in diabetic rats (data not reported). These results
are in agreement with other studies [1,2,10,36]. More-
over, marked dyslipidemia, oxidative stress and inflam-
matory responses were observed in diabetic rats and
these findings are in harmony with various reported
studies [2,36-39].
In the present study, diabetic rats showed a picture
of eosinophilic degeneration and strong Bax immuno-
reaction of pyramidal cells that were contracted with
Figure 4 Photomicrographs of sections in the cerebral cortex of adult male albino rats. (A) control group (B) diabetic group (C) diabetic
cerebral ischemic-reperfused group (D) diabetic group treated with resveratrol (E) diabetic cerebral ischemic-reperfused group treated with resveratrol.
All these micrographs showing AgNOR dots (arrows) in the nuclei of the neuronal cells [A, B, C, D, E AgNOR stain x400 (scale bars represent 10 μm)].
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some of them were surrounded with halos and these
findings are in agreement with Amin et al. [40]. These
results were confirmed with AgNOR stain which showed
a significant decrease in the mean number of AgNOR dotsTable 3 Effect of resveratrol on AgNOR, cresyl violet and mea
N
Mean numbers of AgNOR dots in the nuclei of 50 cells 0.76 ± 0.83
Mean number of viable cells stained with cresyl violet 23.3 ± 3.39
Mean of COX-2 optical density 9.02 ± 2.45
All results were expressed as mean ± SD, (n = 6).
*Significantly different from N at P < 0.05.
#Significantly different from D at P < 0.05.
aSignificantly different from D at P < 0.05.
bSignificantly different from DIR at P < 0.05.
N, D, D + Res, DIR, DIR + Res represent control, diabetic, diabetic treated with resver
ischemic-reperfusion treated with resveratrol groups.in the diabetic group. Bhatt et al. [41] stated that Nu-
cleolar Organiser Regions (NORs) are segments of
DNA, closely associated with nucleoli of the cells on
the short arms of the acrocentric chromosomes, 13, 14,
15, 21 and 22, containing coding gene for Ribosomaln optical density of COX-2 immunohistochemical reaction
D D + Res DIR DIR + Res
0.38 ± 0.68* 0.52 ± 0.78 0.32 ± 0.61* 0.48 ± 0.67
13.6 ± 6.34 17 ± 4.54 9.3 ± 1.24* 14.3 ± 2.86b
21.54 ± 2.95* 13.03 ± 2.34a 32.06 ± 3.74*# 19.34 ± 4.25b
atrol, diabetic with cerebral ischemic-reperfusion, diabetic with cerebral
Figure 5 Photomicrographs of sections in the cerebral cortex of adult male albino rats. (A) control group (B) diabetic group (C) diabetic
cerebral ischemic-reperfused group (D) diabetic group treated with resveratrol (E) diabetic cerebral ischemic-reperfused group treated with
resveratrol. All these micrographs showing surviving neurons (arrows). Viable neurons have lightly stained nuclei while darkly stained neurons with
shrunken cell bodies were excluded from quantification. [A, B, C, D, E cresyl violet stain x400 (scale bars represent 10 μm)].
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thesis. Recent modification of a silver staining technique
allows the interphasic NORs to be visualized under LM
in conventional histopathological sections, where they
are called as “Argyrophilic Nucleolar Organizer Regions(AgNORs)”. Also, cresyl violet stained sections of the
diabetic group showed a decrease (not significant) in
the mean number of viable neurons. Pamidi et al. [32]
found that the diabetic rats exhibited a decrease in the
mean number of surviving neurons, counted using
Figure 6 Photomicrographs of sections in the cerebral cortex of adult male albino rats. (A) control group showing weak positive
immunoreaction for COX-2 (arrow). (B) diabetic group showing strong positive immunoreaction for COX-2 (arrow). (C) diabetic cerebral
ischemic-reperfused group showing strong positive immunoreaction for COX-2 (arrow). (D) diabetic group treated with resveratrol showing
moderate immunoreaction for COX-2 (arrow). (E) diabetic cerebral ischemic-reperfused group treated with resveratrol showing moderate
immunoreaction for COX-2 (arrow). [A, B, C, D, E using Avidin-biotin peroxidase stain with Hx counter stain x400 (scale bars represent 10 μm)].
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Figure 7 Photomicrographs of sections in the cerebral cortex of adult male albino rats. (A) control group showing weak positive
immunoreaction for Bax (arrow). (B) diabetic group showing strong positive immunoreaction for Bax (arrows). (C) diabetic cerebral ischemic-reperfused
group showing strong positive immunoreaction for Bax (arrows). (D) diabetic group treated with resveratrol showing moderate immunoreaction for
Bax (arrows). (E) diabetic cerebral ischemic-reperfused group treated with resveratrol showing moderate immunoreaction for Bax (arrows). [A, B, C, D, E
using Avidin-biotin peroxidase stain with Hx counter stain x400 (scale bars represent 10 μm)].
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Table 4 Effect of resveratrol on apoptotic markers (cerebral apoptotic index and optical density mean of BAX
immunohistochemical reaction)
N D D + Res DIR DIR + Res
Cerebral apoptotic index 0.1 ± 0.01 0.91 ± 0.13* 0.48 ± 0.1a 1.22 ± 0.12*# 0.52 ± 0.08b
Optical density mean of BAX reaction 55.4 ± 6.33 111.8 ± 13.13* 79.71 ± 7.16a 142.4 ± 15.31*# 83.74 ± 7.53b
All results were expressed as mean ± SD, (n = 6).
*Significantly different from N at P < 0.01.
#Significantly different from D at P < 0.01.
aSignificantly different from D at P < 0.05.
bSignificantly different from DIR at P < 0.05.
N, D, D + Res, DIR, DIR + Res represent control, diabetic, diabetic treated with resveratrol, diabetic with cerebral ischemic-reperfusion, diabetic with cerebral
ischemic-reperfusion treated with resveratrol groups.
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compared to the control group. These results indicated
a decrease in the activity of the neuronal cells of the
cerebral cortex which is most probably due to oxidative
stress and apoptosis. It has been reported that neurons
in hyperglycemic environment displayed signs of apop-
tosis due to hyperglycemia-induced oxidative stress [4].
Also, Zhao et al. [42] proved that diabetes upregulated the
expression of Bax and caspase-3 which led to apoptosis of
the pyramidal neurons in STZ induced diabetic rats.
The current study showed that cerebral ischemic-
reperfusion for diabetic rats specifically exaggerated oxi-
dative stress, inflammation and apoptosis including a
significant increase of cerebral content of MDA, upregu-
lation of COX-2 gene expression, a severe depletion of
cerebral GSH and IL-4 contents and a significant in-
crease in the apoptotic index and the optical density of
Bax reaction. The major pathological mechanisms of
cerebral ischemic injury include excitotoxicity, oxidative
stress, inflammation, and apoptosis, which are associated
with mitochondrial dysfunction and a rapid decrease of
adenosine triphosphate (ATP). Depletion of GSH in
cerebral ischemia leads to lipid peroxidation and neur-
onal cell apoptosis, in which the Bcl-2 family proteins
(e.g. anti-apoptotic Bcl-2, pro-apoptotic Bax) are involved
[43,44]. Furthermore, there is evidence that elevated ROS
levels within mitochondria generated by cerebral ischemic-
reperfusion alters the expression of pro-apoptotic factor
Bax, anti-apoptotic Bcl-2 and caspase-3 [43,45].
Histologically, the cerebral tissues of cerebral ischemic-
reperfusion diabetic rats showed features of eosinophilic
degeneration and some neurons were surrounded with
halos. These findings are in agreement with Levison Damr
[46] who stated that cerebral ischemia or anoxia led to eo-
sinophilic degeneration, mostly of pyramidal cells of cere-
bral cortex as the whole cell shrinks, contracts, the
cytoplasm loses its Nissl granules and becomes eosino-
philic. The nucleus is basophilic, hyperchromatic, small
and pyknotic and moves to more peripheral position and
the nucleolus disappear. Also, AgNOR stained sections
showed significant decrease in mean number of AgNOR
dots. Furthermore, cresyl violet stain showed a significantdecrease in the mean number of viable neurons. Pamidi
et al. [32] supported our findings as they found that the
untreated diabetes mellitus coupled with stress can induce
highly significant damage in the neurons of rat cerebral
which was shown by a significant decrease in the number
of surviving neurons of cresyl violet stained sections.
In the present study, treatment of the diabetic and the
diabetic ischemic-reperfused rats with resveratrol in-
duced a remarkable reduction of plasma glucose level
and corrected the diabetic dyslipidemia. These results are
in harmony with other studies [16,47] which reported that
resveratrol reduced blood TAG, TC and LDL-C and ele-
vated HDL-C in hypercholesterolemic rats. Moreover,
Gnoni and Paglialonga [48] reported that resveratrol de-
creased fatty acid and TAG synthesis through inhibition of
fatty acid synthase in isolated rat hepatocytes. This may
represent a potential mechanism contributing to the re-
ported hypolipidemic effect of resveratrol.
Administration of resveratrol significantly ameliorated
diabetes-induced oxidative stress, inflammation and apop-
tosis. Various studies suggested the neuroprotective
activity of resveratrol through its antioxidant and anti-
inflammatory properities [15,49,50]. Resveratrol was re-
ported to inhibit lipid peroxidation and neuronal cell death
induced by oxidative stress and enhance various antioxi-
dant enzymes [10,51]. These effects could be attributed to
its property as a potent scavenger of ROS and RNS.
Zhang et al. [49] demonstrated interesting anti-
inflammatory activities for resveratrol. It can attenuate
the activation of immune cells and the subsequent syn-
thesis and release of pro-inflammatory mediators through
the inhibition of the transcriptional factors such as NF-κB.
In addition, it has been shown to inhibit the activation of
microglia, cerebral microphages and reduce the produc-
tion of pro-inflammatory mediators. Therefore, resveratrol
may exert neuroprotection in neurodegenerative diseases
accompanied by microglial activation. This hypothesis is
best evidenced with the present study showing that resver-
atrol increased cerebral IL-4, anti-inflammatory cytokine
targeting the microglia, in treated animals.
IL-4 was reported to suppress NF-κB which is a tran-
scription factor that resides in the cytoplasm of every
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activation is induced by a wide variety of agents includ-
ing stress, inflammatory stimuli and free radicals. Activa-
tion of NF-kB upregulates the expression of COX-2 (an
inflammatory enzyme) [52]. The present study reported a
significant upregulation of COX-2 gene expression in
cerebral cortex of diabetic and diabetic cerebral ischemic-
reperfused rats while resveratrol treatment downregulated
COX-2 gene expression of treated animals. These results
are in accordance with Kumar and Sharma [18] who
stated that COX-2 enzyme is an inducible enzyme, be-
coming abundant in activated macrophages and other
cells at sites of inflammation. This enzyme has been re-
ported to be elevated in metabolic diseases as well as in
diabetic condition.
The present study showed that treatment of the dia-
betic and the diabetic ischemic-reperfused groups with
resveratrol reduced the extent of eosinophilic degener-
ation and apoptosis of neurons and showed moderate
improvement of the cerebral tissues. Also, the mean
number of AgNOR dots showed an increase (not signifi-
cant) and the mean number of viable neurons stained
with cresyl violet stain showed an increase (significant in
the diabetic ischemic-reperfused group and not signifi-
cant in the diabetic group) upon treatment with resvera-
trol. Therefore, these results showed that resveratrol has
anti-apoptotic potency in consistent with previous reports
[44,53,54]. Also, [55] reported that resveratrol treatment
attenuated rat cerebral damage after cerebral ischemia by
downregulation of Bax expression.
The findings of the present study introduced new in-
sights into the pathogenesis and treatment of neurodegen-
erative diseases, especially diabetic cerebral complications.Conclusion
In conclusion, beside antioxidant properties of resveratrol,
it exerted beneficial hypoglycemic, hypolipidemic and anti-
inflammatory effects regarding diabetes-induced cerebral
complications in diabetic and diabetic cerebral ischemic-
reperfused rats. These effects suggest resveratrol as a prom-
ising neuroprotective agent in diabetes-induced cerebral
complications. Therefore, this study recommended such
drug in diabetic complications especially neuropathy to
limit the risks of cerebral complications.Competing interests
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